IJCEMR

Article http://dx.doi.org/10.26855/ijcemr.2024.01.001

Research Progress on Influencing Factors, Mechanisms, and Therapeutic Regimens of Adverse Emotions in COPD Patients

TOTAL VIEWS: 488

Rong Xiao, Ruicheng Hu*

The First Affiliated Hospital of Hunan Normal University (Hunan Provincial People's Hospital), Changsha, Hunan, China.

*Corresponding author: Ruicheng Hu

Published: December 30,2023

Abstract

Chronic obstructive pulmonary disease (COPD) is a serious respiratory system disease in China and even the world, which seriously affects patients’ health and quality of life. In addition to COPD symptoms, the accompanying anxiety, depression, and other adverse emotions have gradually attracted widespread attention. Based on the summary of previous literature, this article summarizes the influencing factors of adverse emotions in COPD patients, including smoking, chronic pain, activity limitation, drug effect, gender, fatigue, etc. Clinical treatment can be taken through continuous and close observation of the influencing factors of adverse emotions, and timely and effective intervention measures can be taken for high-risk groups. At present, the exact pathogenesis of anxiety and depression in COPD patients is still unclear. It involves multiple complex pathophysiological factors such as hypoxemia and chronic inflammation, which may also include behavioral factors such as active smoking and tobacco addiction, as well as other factors such as social isolation, complications, declined physical function, and frequent re hospitalization. This study summarizes several mechanisms such as hyperventilation, carbon dioxide retention, hypoxemia, inflammation, immune regulation, cognitive behaviors, and sleep disorders so as to determine the possible mechanisms of anxiety, depression, and other adverse emotions in COPD patients and to assist the clinical search for effective therapeutic targets. Finally, this article summarizes the treatment progress of adverse emotions in COPD patients mainly through antipsychotics and TCM therapy, individualized breathing intervention, and cognitive behavioral therapy.

References

[1] Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (2024 Report) [EB/OL]. [2024-11-12]. https://goldcopd. org/2024-gold-reports/.

[2] Celli BR, Wedzicha JA. Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease [J]. N Engl J Med, 2019, 381(13):1257-1266. doi: 10.1056/NEJMra1900500.

[3] Naberhaus T. Chronic Obstructive Pulmonary Disease, Part 2: A Review of Pharmacotherapy Options [J]. Sr Care Pharm, 2023, 38(7):266-275. doi: 10.4140/TCP.n.2023.266.

[4] Lin FL, Yeh ML, Lai YH, et al. Two-month breathing-based walking improves anxiety, depression, dyspnoea and quality of life in chronic obstructive pulmonary disease: A randomised controlled study [J]. J Clin Nurs, 2019, 28(19-20):3632-3640. doi: 10.1111/jocn.14960. Epub 2019 Jun 28.

[5] Liu, Y., Tian, X., Guo, X., et al. Investigation of Anxiety and Depression in Patients with Chronic Obstructive Pulmonary Dis-ease. Chinese Journal of Respiration and Critical Care Medicine, 2020, 19(5): 425-429. DOI: 10.7507/1671-6205.202001049.

[6] You, Z., Wang, G. Assessment and Countermeasures for Anxiety and Depression in Chronic Obstructive Pulmonary Disease. Chinese Journal of Practical Internal Medicine, 2020, 40(10): 805-809. DOI: 10.19538/j.nk2020100104.

[7] Yohannes AM, Kaplan A, Hanania NA. Anxiety and depression in chronic obstructive pulmonary disease: recognition and management [J]. Cleve Clin J Med, 2018, 85(Suppl 1): S11-S18. doi: 10.3949/ccjm.85.s1.03.

[8] Qi, Y. Application of Psychological Nursing in Patients with Chronic Obstructive Pulmonary Disease Complicated with Anxiety and Depression. Nursing Research, 2016, 30(36): 4599-4600. DOI: 10.3969/j.issn.1009-6493.2016.36.044.

[9] Au Yeung SL, Li AM, He B, et al. Association of smoking, lung function and COPD in COVID-19 risk: a two-step Mendelian randomization study [J]. Addiction, 2022, 117(7):2027-2036. doi: 10.1111/add.15852. Epub 2022 Mar 7.

[10] Chang JT, Meza R, Levy DT, et al. Prediction of COPD risk accounting for time-varying smoking exposures [J]. PLoS One, 2021, 16(3):e0248535. doi: 10.1371/journal.pone.0248535.

[11] Yu, Y., Liu, M. Analysis of Risk Factors for Anxiety and Depression in Elderly Patients with Chronic Obstructive Pulmonary Disease. Chinese Journal of Modern Medicine, 2019, 29(21): 65-70. DOI: 10.3969/j.issn.1005-8982.2019.21.013.

[12] Bugajski A, Morgan H, Wills W, et al. Anxiety and Depressive Symptoms in Patients with COPD: Modifiable Explanatory Factors [J]. West J Nurs Res, 2023, 45(4):316-326. doi: 10.1177/01939459221129949. Epub 2022 Oct 16.

[13] Shibata M, Ohara T, Hosoi M, et al. Emotional Loneliness Is Associated with a Risk of Dementia in a General Japanese Older Population: The Hisayama Study [J]. J Gerontol B Psychol Sci Soc Sci, 2021, 76(9):1756-1766. doi: 10.1093/geronb/gbaa196.

[14] Liu, Q., Li, F. Investigation and Analysis of Anxiety and Depression in Patients with Chronic Obstructive Pulmonary Disease. Modern Hospitals, 2019, 19(6): 933-936. DOI: 10.3969/j.issn.1671-332X.2019.06.045.

[15] Lian, C., Zhang, J. Investigation of Anxiety and Depression in Hospitalized Patients with Chronic Obstructive Pulmonary Disease and Related Influencing Factors. Chinese Journal of Primary Medicine and Pharmacy, 2016, 23(8): 1126-1129.

DOI: 10.3760/cma.j.issn.1008-6706.2016.08.002.

[16] Wang, R., Xu, J., Liu, H. Analysis of Factors Related to Emotional Disorders in Patients with Chronic Obstructive Pulmonary Disease in Stable Periods. Chinese Journal of Medicinal Guide, 2016, 16(4): 463-466. DOI: 10.11655/zgywylc2016.04.003.

[17] de Miguel-Díez J, Lopez-de-Andres A, Jimenez-Garcia R, et al. National Trends in Prevalence of Depression in Men and Women with Chronic Obstructive Pulmonary Disease Hospitalized in Spain, 2016-2020 [J]. J Clin Med, 2022, 11(21):6337. doi: 10.3390/jcm11216337.

[18] Berman AR. Management of patients with end-stage chronic obstructive pulmonary disease [J]. Prim Care, 2011, 38(2):277-97, viii-ix. doi: 10.1016/j.pop.2011.03.008.

[19] Ding, J. Analysis of Factors Related to Anxiety and Depression in Patients with Chronic Obstructive Pulmonary Disease. Journal of Clinical Pulmonary Medicine, 2018, 23(4): 690-693. DOI: 10.3969/j.issn.1009-6663.2018.04.029.

[20] Ebadi Z, Goërtz YMJ, Van Herck M, et al. The prevalence and related factors of fatigue in patients with COPD: a systematic review [J]. Eur Respir Rev, 2021, 30(160):200298. doi: 10.1183/16000617.0298-2020.

[21] Gruet M. Fatigue in Chronic Respiratory Diseases: Theoretical Framework and Implications for Real-Life Performance and Rehabilitation [J]. Front Physiol, 2018, 9:1285. doi: 10.3389/fphys.2018.01285.

[22] Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (2022 Report) [EB/OL]. [2021-11-22]. https://goldcopd. org/2022-gold-reports-2/.

[23] Fang, Z., Li, X., Yang, X., et al. Prospective Cohort Study on the Impact of Fatigue on Acute Exacerbation in Patients with Chronic Obstructive Pulmonary Disease. Chinese Journal of General Practice, 2023, 26(3): 287-292. DOI: 10.12114/j.issn.1007-9572.2022.0342.

[24] Volpato E, Toniolo S, Pagnini F, et al. The Relationship Between Anxiety, Depression and Treatment Adherence in Chronic Ob-structive Pulmonary Disease: A Systematic Review [J]. Int J Chron Obstruct Pulmon Dis, 2021, 16:2001-2021. doi: 10.2147/COPD.S313841.

[25] Kawachi S, Fujimoto K. Efficacy of tiotropium and olodaterol combination therapy on dynamic lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before and after treatment study [J]. Int J Chron Obstruct Pulmon Dis, 2019, 14:1167-1176. doi: 10.2147/COPD.S201106. PMID: 31213796.

[26] Li, G., Wang, J., Wang, M., et al. Effects of Daytime Hypersomnia and Subjective Decline in Sleep Quality on Neuro-Psychological Characteristics of Elderly Patients with Obstructive Sleep Apnea-Hypopnea Syndrome. Jiangsu Medicine, 2022, 48(3): 237-242. DOI: 10.19460/j.cnki.0253-3685.2022.03.005.

[27] Boukhenouna S, Wilson Ma, Bahmed K, et al. Reactive Oxygen Species in Chronic Obstructive Pulmonary Disease [J]. Oxid Med Cell Longev, 2018, 2018:5730395. doi: 10.1155/2018/5730395.

[28] Zuberi FF, Zuberi BF, Ali FS, et al. Muscle weakness assessment in non-hypoxemic COPD out-patients at tertiary care hospitals[J]. Pak J Med Sci, 2021, 37(2):536-542. doi: 10.12669/pjms.37.2.3127. PMID: 33679946.

[29] Rivera PM, Proppe CE, Beltran E, et al. Acute Effects of Local Ischemic Hypoxia and Systemic Hypoxemia on Neuromuscular and Cognitive Function [J]. High Alt Med Biol, 2022, 23(1):18-25. doi: 10.1089/ham.2021.0096. Epub 2021 Dec 21.

[30] Yohannes AM, Kaplan A, Hanania NA. Anxiety and depression in chronic obstructive pulmonary disease: recognition and management [J]. Cleve Clin J Med, 2018, 85(Suppl 1): S11-S18. doi: 10.3949/ccjm.85.s1.03.

[31] Beurel E, Toups M, Nemeroff CB. The Bidirectional Relationship of Depression and Inflammation: Double Trouble [J]. Neuron, 2020, 107(2):234-256. doi: 10.1016/j.neuron.2020.06.002. Epub 2020 Jun 17.

[32] Xu K, Li X. Risk factors for depression in patients with chronic obstructive pulmonary disease [J]. Med Sci Monit, 2018, 24: 1417-1423. doi: 10.12659/msm.904969.

[33] Drevets WC, Wittenberg GM, Bullmore ET, et al. Immune targets for therapeutic development in depression: towards precision medicine [J]. Nat Rev Drug Discov, 2022, 21(3):224-244. doi: 10.1038/s41573-021-00368-1. Epub 2022 Jan 17.

[34] Dudek KA, Dion-Albert L, Kaufmann FN, et al. Neurobiology of resilience in depression: immune and vascular insights from human and animal studies [J]. Eur J Neurosci, 2021, 53(1):183-221. doi: 10.1111/ejn.14547. Epub 2019 Sep 13.

[35] Zhou, X.P., Fang, R.H. Survey and Analysis of Anxiety and Depression in Patients with Chronic Obstructive Pulmonary Disease in General Wards. Chinese Journal of General Practice, 2022, 20(6): 1003-1006. DOI: 10.16766/j.cnki.issn.1674-4152.002510.

[36] Gulibakangmu, A., Abdusalamu, A., Ma, R., et al. Influence of Sleep Disorders on Anxiety and Depression Status and Short-Term Prognosis in Elderly Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Chinese Journal of Clin-ical Pulmonary Medicine, 2022, 27(12): 1882-1885. DOI: 10.3969/j.issn.1009-6663.2022.12.019.

[37] Ni, X.Q., Gao, Y.L., Li, Z.H. Effects of Zero-Defect Nursing Services on Anxiety and Depression Scores, Tolerance, and Forced Expiratory Volume in 1 Second in COPD Patients with Respiratory Failure. Modern Medicine, 2020, 48(2): 288-291. DOI: 10.3969/j.issn.1671-7562.2020.02.031.

[38] Pollok J, Van Agteren JE, Esterman AJ, et al. Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease [J]. Cochrane Database Syst Rev, 2019, 3(3):CD012347. doi: 10.1002/14651858.CD012347.pub2.

[39] Ji, X.Q., Zhao, Y.X., Geng, Y., et al. The Impact of Diversified Nursing on Pulmonary Function and Psychological Status in COPD Patients with Lung Cancer Undergoing Chemotherapy. Qilu Nursing Journal, 2022, 28(13): 51-53. DOI: 10.3969/j.issn.1006-7256.2022.13.015.

[40] Yohannes AM, Jin JW, Kunik ME. Benefit-Risk Assessment of Psychotropic Drugs in Older Patients with Chronic Obstructive Pulmonary Disease [J]. Drugs Aging, 2022, 39(5):323-332. doi: 10.1007/s40266-022-00935-0. Epub 2022 Apr 19.

[41] Wu, P.Z., Liang, X.X., Wang, S.L. Screening of Tryptophan 2,3-Dioxygenase Inhibitors in Chaihu Shugan Powder and Study on Antidepressant Effects. Chinese Herbal Medicines, 2023, 54(9): 2812-2821. DOI: 10.7501/j.issn.0253-2670.2023.09.014.

[42] Qian MYY, Politis J, THOMPSON M, et al. Individualized breathlessness interventions may improve outcomes in patients with advanced COPD [J]. Respirology, 2018, 23(12):1146-1151. doi: 10.1111/resp.13324. Epub 2018 May 15.

[43] Grosbois JM, Gephine S, Kyheng M, et al. Physical and affective components of dyspnoea are improved by pulmonary rehabilitation in COPD[J]. BMJ Open Respir Res, 2022, 9(1):e001160. doi: 10.1136/bmjresp-2021-001160.

[44] Mathisen TF, Rosenvinge JH, Friborg O, et al. Is physical exercise and dietary therapy a feasible alternative to cognitive behavior therapy in treatment of eating disorders? A randomized controlled trial of two group therapies [J]. Int J Eat Disord, 2020, 53(4):574-585. doi: 10.1002/eat.23228. Epub 2020 Jan 16.

[45] Stefan S, Cristea IA, Szentagotai Tatar A, et al. Cognitive-behavioral therapy (CBT) for generalized anxiety disorder: Contrasting various CBT approaches in a randomized clinical trial [J]. J Clin Psychol, 2019, 75(7):1188-1202. doi: 10.1002/jclp.22779. Epub 2019 Apr 20.

[46] Wu, Y., Duan, H.W., Chen, X. Meta-Analysis of Cognitive Behavioral Therapy for Improving Depression and Blood Sugar in Diabetic Patients. Journal of Nursing, 2018, 33(3): 23-27. DOI: 10.3870/j.issn.1001-4152.2018.03.023.

[47] Ye M, Du K, Zhou J, et al. A meta-analysis of the efficacy of cognitive behavior therapy on quality of life and psychological health of breast cancer survivors and patients[J]. Psychooncology, 2018, 27(7):1695-1703. doi: 10.1002/pon.4687. Epub 2018 Mar 26.

[48] Singh SJ, Baldwin MM, Daynes E, et al. Respiratory sequelae of COVID-19: pulmonary and extrapulmonary origins, and approaches to clinical care and rehabilitation [J]. Lancet Respir Med, 2023, 11(8):709-725. doi: 10.1016/S2213-2600(23)00159-5. Epub 2023 May 19.

How to cite this paper

Research Progress on Influencing Factors, Mechanisms, and Therapeutic Regimens of Adverse Emotions in COPD Patients

How to cite this paper: Rong Xiao, Ruicheng Hu. (2024) Research Progress on Influencing Factors, Mechanisms, and Therapeutic Regimens of Adverse Emotions in COPD PatientsInternational Journal of Clinical and Experimental Medicine Research, 8(1), 1-7.

DOI: http://dx.doi.org/10.26855/ijcemr.2024.01.001